NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 319 filers reported holding NOVOCURE LTD in Q3 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,826 | -17.9% | 44 | +18.9% | 0.00% | – |
| Q1 2023 | $2,225 | -18.0% | 37 | 0.0% | 0.00% | – |
| Q4 2022 | $2,714 | -9.5% | 37 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | -25.0% | 37 | -40.3% | 0.00% | – |
| Q2 2022 | $4,000 | -50.0% | 62 | -38.0% | 0.00% | -100.0% |
| Q1 2022 | $8,000 | +300.0% | 100 | +376.2% | 0.00% | – |
| Q4 2021 | $2,000 | -60.0% | 21 | -47.5% | 0.00% | -100.0% |
| Q3 2021 | $5,000 | -28.6% | 40 | +25.0% | 0.00% | 0.0% |
| Q2 2021 | $7,000 | +250.0% | 32 | +88.2% | 0.00% | – |
| Q1 2021 | $2,000 | -81.8% | 17 | -94.7% | 0.00% | -100.0% |
| Q4 2018 | $11,000 | – | 321 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |